France
· Delayed Price · Currency is EUR EPA: ALOPM Company Description
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business.
The company’s pipeline includes OPM-101, a potentially inhibitor of the RIPK2 target, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; OPM-102, a novel inhibitor that is in preclinical studies for the treatment of cancer; and OPM-201, a potential LRRK2 inhibitor, which is in Phase 1 clinical trial for the treatment of Parkinson’s disease.
It is also developing drugs for the treatment of pancreatic and other cancers. The company has a strategic collaboration agreement with Navigo Proteins GmbH for the discovery and development of new systemic radiotheranostic agents.
Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.
| Country | France |
| Founded | 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Philippe Genne |
Contact Details
Address: 18 rue Jean Mazen Dijon, 21000 France | |
| Phone | 33 310 451 820 |
| Website | oncodesign.com |
Stock Details
| Ticker Symbol | ALOPM |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Philippe Genne Ph.D. | Chairman and Chief Executive Officer |
| Arnaud Lafforgue | Chief Financial and Administrative Officer |
| Karine Lignel | Chief Operating Officer |
| Dr. Jan Hoflack Ph.D. | Chief Scientific Officer |
| Thierry Billoue | Chief Human Resources Officer |